New research shows that inhibiting overactive LRRK2 enzymes could stabilize Parkinson's disease progression, with Stanford ...

The results of experiments in mice models were "astounding," said biochemist Suzanne Pfeffer of Stanford University.

The company completed a clinical trial at nine centers across the U.S., Europe and Asia before it received FDA approval.

Parkinson's disease is a neurogenerative disease that affects more than 1 million people in the U.S. While some cases are ...

Parkinson’s disease affects more than 10 million people worldwide. Discover its causes, symptoms, and the latest innovations in diagnosis and treatment.

New Parkinson’s treatment developed at Stanford could help millions Adaptive Deep Brain Stimulation isn’t a cure — but it’s a total game changer ...

Key Background. Parkinson’s disease is a degenerative neurological disorder with no cure. It largely affects people over 50 years of age and, after Alzheimer’s, is the second-most common ...

Treatment for Parkinson's focuses on managing its many symptoms, as there is no cure. But a new stem cell therapy developed at Memorial Sloan Kettering Cancer Center for advanced Parkinson's is ...

Dr. Helen Bronte-Stewart developed adaptive Deep Brain Stimulation (aDBS) as a more responsive and refined treatment for the symptoms of Parkinson’s Disease – the FDA approved aDBS for the ...

N E W   Y O R K, June 12 -- Leading neurologists say a change in drug treatment for Parkinson's patients could reduce uncontrollable body tremors for many in the early stages of the disease ...

Scientists have demonstrated an exciting proof of concept for treating Parkinson's in mice, whereby inhibiting a single gene is a one-time treatment eradicated the disease entirely, and kept it at ...